Caspase 6 Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Caspase 6, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Caspase 6 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Companies Involved in Caspase 6 Development are Conatus Pharmaceuticals Inc, New World Laboratories Inc
The Caspase 6 pipeline guide also reviews of key players involved in therapeutic development for Caspase 6 and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 5 and 1 respectively.
Scope of this report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Caspase 6. The pipeline guide reviews pipeline therapeutics for Caspase 6 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Caspase 6 therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Caspase 6 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Caspase 6.
- This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Caspase 6. Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Caspase 6 pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
According to the recently published report ‘Caspase 6 – Pipeline Review, H1 2017’; Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 126.96.36.199) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 188.8.131.52) – Caspase-6 is an enzyme encoded by the CASP6 gene. It is involved in the activation cascade of caspases responsible for apoptosis execution. It cleaves poly (ADP-ribose) polymerase.
The report ‘Caspase 6 – Pipeline Review, H1 2017’ outlays comprehensive information on the Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Caspase 6 (Apoptotic Protease Mch 2 or CASP6 or EC 220.127.116.11) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Oncology and Respiratory which include indications Huntington Disease, Alzheimer’s Disease, Autoimmune Hepatitis, Colorectal Cancer, Hepatitis C, Hepatocellular Carcinoma, Liver Cirrhosis, Liver Failure (Hepatic Insufficiency), Liver Transplant Rejection, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Pancreatic Islet Transplant Rejection, Portal Hypertension, Primary Sclerosing Cholangitis, Pulmonary Fibrosis and Renal Failure.